|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Metastatic gastric cancer treatment: Second line and beyond显示文摘Advanced gastric cancer(a GC), not amenable to curative surgery, is still a burdensome illness tormenting afflicted patients and their healthcare providers. Whereas combination chemotherapy has been shown to improve survival and tumor related symptoms in the frontline setting, second-line therapy(SLT) is subject to much debate in the scientific community, mainly because of the debilitating effects of GC, which would impede the administration of cytotoxic therapy. Recent data has provided sufficient evidence for the safe use of SLT in patients with an adequate performance status. Taxanes, Irinotecan and even some Fluoropyrimidine analogs were found to provide a survival advantage in this subset of patients. Most importantly, quality of life measures were also improved through the use of adequate therapy. Even more pertinent were the findings involving antiangiogenic agents, which would add measurable improvements without significantly jeopardizing the patients' well-being. Further lines of therapy are cause for much more debate nowadays, but specific targeted agents have shown considerable promise in this context. We herein review noteworthy published data involving the use of additional lines of the therapy after failure of standard frontline therapies in patients with a GC. | Marwan Ghosn Samer Tabchi Hampig Raphael Kourie Mustapha Tehfe | 2016 | World Journal of Gastroenterology2016，22，11： | 10 |
| 2 | Optimum chemotherapy in the management of metastatic pancreatic cancer显示文摘Pancreatic cancer is one of the most devastating solid tumors,and it remains one of the most difficult to treat.The treatment of metastatic pancreatic cancer(MPC)is systemic,based on chemotherapy or best supportive care,depending on the performance status of the patient.Two chemotherapeutical regimens have produced substantial benefits in the treatment of MPC:gemcitabine in 1997;and FOLFIRIONOX in 2011.FOLFIRINOX improved the natural history of MPC,with overall survival(OS)of 11.1 mo.Nab-paclitaxel associated with gemcitabine is a newly approved regimen for MPC,with a median OS of 8.6 mo.Despite multiple trials,this targeted therapy was not efficient in the treatment of MPC.Many new molecules targeting the proliferation and survival pathways,immune response,oncofetal signaling and the epigenetic changes are currently undergoing phaseⅠandⅡtrials for the treatment of MPC,with many promising results. | Marwan Ghosn Hampig Raphael Kourie Fadi El Karak Colette Hanna Joelle Antoun Dolly Nasr | 2014 | World Journal of Gastroenterology2014，20，9： | 7 |
| 3 | Anal cancer treatment:Current status and future perspectives显示文摘Anal cancers(AC)are relatively rare tumors.Their incidence is increasing,particularly among men who have sex with other men due to widespread infection by human papilloma virus.The majority of anal cancers are squamous cell carcinomas,and they are treated according to stage.In local and locally advanced AC,concomitant chemoradiation therapy based on mitomycin C and 5-Fluorouracil(5-FU)is the current best treatment,while metastatic AC,chemotherapy with 5-FU and cisplatin remains the gold standard.There are no indications for induction or maintenance therapies in locally advanced tumors.Many novel strategies,such as targeted therapies,vaccination,immunotherapy and photodynamic therapy are in clinical trials for the treatment of AC,with promising results in some indications. | Marwan Ghosn Hampig Raphael Kourie Pamela Abdayem Joelle Antoun Dolly Nasr | 2015 | World Journal of Gastroenterology2015，21，8： | 4 |
| 4 | Optimum chemotherapy for the management of advanced biliary tract cancer显示文摘Biliary tract cancers(BTCs) are highly fatal malignancies, which are often diagnosed at an advanced stage and have relatively poor prognosis.The treatment of patients with advanced BTC is systemic, based on chemotherapy or best supportive care, depending on their performance status.Despite clinical trials studyingmany chemotherapeutic regimens and targeted therapies for the treatment of BTC, the standard of care for advanced BTC remains the combination of gemcitabine with cisplatin.Many new molecules targeting proliferation and survival pathways, the immune response and angiogenesis are currently undergoing phase Ⅰ and Ⅱ trials for the treatment of advanced BTC with promising results. | Marwan Ghosn Hampig Raphael Kourie Elie El Rassy Ralph Chebib Fadi El Karak Colette Hanna Dolly Nasr | 2015 | World Journal of Gastroenterology2015，21，14： | 2 |
| 5 | Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature显示文摘Ampullary carcinoma(AC) is a rare gastrointestinal tumor without clear treatment recommendations.The management of this tumor is usually extrapolated from the treatment of pancreatic,biliary duct and intestinal cancers.Few papers have studied the AC as an independent entity and yet succombs to several limitations.These studies were retrospective single institutional experiences with limited sample sizes recruited over a long period of time.Unlike metastatic ACs where chemotherapy is the only recommended option,localized AC once excised may be approached by either chemotherapy alone or concomitant chemoradiation therapy.In this review,we report the overall survival and recurrence factors of more than 1000 patients from all the studies treating exclusively ACs.We also review the medical treatment of this tumor and conclude to the necessity of multi-institutional randomized controlled studies for AC exclusively. | Marwan Ghosn Hampig Raphael Kourie Elie El Rassy Fady Ghassan Haddad Colette Hanna Fadi El Karak Dolly Nasr | 2016 | World Journal of Gastrointestinal Oncology2016，8，10： | 2 |
| 6 | Dilemma of first line regimens in metastatic pancreatic adenocarcinoma显示文摘Pancreatic cancer is one of the deadliest cancers,ranking fourth among cancer-related deaths. Despite all the major molecular advances and treatment breakthroughs, mainly targeted therapies, the cornerstone treatment of metastatic pancreatic cancer(m PC) remains cytotoxic chemotherapy. In 2016, more than 40 years after the introduction of gemcitabine in the management of m PC, the best choice for first-line treatment has not yet been fully elucidated. Two main strategies have been adopted to enhance treatment efficacy. The first strategy is based on combining non-cross resistant drugs, while the second option includes the development of newer generations of chemotherapy. More recently, two new regimens, FOLFIRINOX and gemcitabine/nab-paclitaxel(GNP), have both been shown to improve overall survival in comparison with gemcitabine alone, at the cost of increased toxicity. Therefore, the best choice for first line therapy is a matter of debate. For some authors, FOLFIRINOX should be the first choice in patients with an Eastern Cooperative Oncology Group score(0-1) given its lower hazard ratio. However, others do not share this opinion. In this paper, we review the main comparison points between FOLFIRINOX and GNP. We analyze the two pivotal trials to determine the similarities and differences in study design. In addition, we compare the toxicity profile of the two regimens as well as the impact on quality of life. Finally, we present studies revealing real life experiences and review the advantages and disadvantages of possible second-line therapies including their cost effectiveness. | Marwan Ghosn Tony Ibrahim Tarek Assi Elie El Rassy Hampig Raphael Kourie Joseph Kattan | 2016 | World Journal of Gastroenterology2016，22，46： | 2 |
| 7 | Freeze–thaw degradation of FRP–concrete interface: Impact on cohesive fracture response显示文摘 | Kolluru V. Subramaniam Mohamad Ali-Ahmad Michel Ghosn | 2008 | Engineering Fracture Mechanics2008，，13： | 2 |
| 8 | Monitoring of glucose permeability in monkey skin in vivo using optical coherence tomography显示文摘 | Mohamad G Ghosn Narendran Sudheendran Mark Wendt | 2010 | J Biophotonics2010，3，12： | 1 |
| 9 | Seismic fragility of con- tinuous steel highway bridges in New York State显示文摘 | Pan Y Agrawal A K Ghosn M | 2007 | Jour- nal of Bridge Engineering2007，12，6： | 1 |
| 10 | Concomitant occurrence of kimura disease and mycosis fungoides in a Lebanese woman: significance and response to rituximab显示文摘 | Ghosn S Bahhady R Mahfouz R | 2009 | Am J Dermatopathol2009，31，8： | 1 |
| 11 | Chloride-induced corrosion of reinforced concrete bridge decks显示文摘 | Mumtaz K Kassir Michel Ghosn | 2002 | Cement and Concrete Research2002，，1： | 1 |
| 12 | Folfox-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer显示文摘 | Ghosn M Farhat F Kattan J | 2007 | Am J Clin Oncol2007，30，1： | 1 |
| 13 | 3D simplified finite el- ements analysis of load and contact angle in a slewing ball bearing 显示文摘 | DAIDIE A CHAIB Z GHOSN A | 2008 | Journal of Mechanical Design2008，130，08： | 1 |
| 14 | Seismic Fragility of Continuous Steel Highway Bridges in New York State 显示文摘 | PAN Y AGRAWAL A K GHOSN M | 2007 | Journal of Bridge Engineering2007，12，6： | 1 |
| 15 | Seismic Fragility of Retrofitted Multispan Continuous Steel Bridge in New York 显示文摘 | AGRAWAL A K GHOSN M A1AMPALLI S | 2012 | Journal of Bridge Engineering2012，17，4： | 1 |
| 16 | FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer 显示文摘 | Ghosn M Farhat F Kattan J | 2007 | Am J Clin Oncol2007，30，1： | 1 |
| 17 | 3D Simplified Finite Ele- ments Analysis of Load and Contact Angle in a Slewing Ball Bearing显示文摘 | Daidi6 A Chaib Z Ghosn A | 2008 | Journal of Mechanical Design2008，130，8： | 1 |
| 18 | 显示文摘 | DALTON L R HARPER A W GHOSN R S | 1995 | Chem Mater1995，7，6： | 1 |
| 19 | Development of B cells and erythrocytes is specifically impaired by the drug celastrol in mice显示文摘 | Kusy S Ghosn EE Herzenberg LA | 2012 | PLo S One2012，7，35： | 1 |
| 20 | Experience with palliative care in patients with advanced cancer at a tertiary care hospital in a developing eountry显示文摘 | Ghosn Marwan Boutros Ce1ine Geara Salma | 2011 | Supportive Care in Canc- er2011，19，04： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员